瑞舒伐他汀对高胆固醇血症患者血清尿酸水平的影响

Effect of rosuvastatin on serum uric acid levels in patients with hypercholesterolemia

关键词:  瑞舒伐他汀  尿酸  高胆固醇血症

Key words:  rosuvastatin  uric acid  hypercholesterolemia

摘要:

[目的] 探讨瑞舒伐他汀对高胆固醇血症患者血清尿酸水平的影响。[方法] 选取90例高胆固醇血症患者，随机分为两组：瑞舒伐他汀组45例，口服瑞舒伐他汀10 mg/d；阿托伐他汀组45例，口服阿托伐他汀20 mg/d。疗程3个月，观察用药前、后血脂和血清尿酸水平的变化。并根据初始血清尿酸水平将两组再各分为高尿酸血症组和正常尿酸组。[结果] (1) 用药后瑞舒伐他汀组和阿托伐他汀组和阿托伐他汀组患者总胆固醇和低密度脂蛋白胆固醇水平较用药前均明显下降，差异有显著性意义（P<0.05），两组之间下降幅度差异无显著性意义（P>0.05）；(2) 用药后瑞舒伐他汀组和阿托伐他汀组患者血清尿酸水平均较用药前明显下降，差异有显著性意义（P<0.05），其中高尿酸血症患者与正常尿酸患者相比尿酸下降幅度更大（P<0.05）。(3) 瑞舒伐他汀组与阿托伐他汀组相比，高尿酸血症患者和正常尿酸患者尿酸下降幅度差异均无显著性意义（P>0.05）。[结论] 瑞舒伐他汀在降低高胆固醇血症患者血脂水平同时亦可降低血清尿酸水平，对高尿酸血症患者尿酸降低幅度更大，其疗效与阿托伐他汀相当。

Abstract:

[Objective] To discuss the effect of rosuvastatin on serum uric acid levels in patients with hypercholesterolemia. [Methods] Ninety patients with hypercholesterolemia were randomized into two groups: rosuvastatin group (n=45) patients received rosuvastatin 10 mg / d for 3 months; atorvastatin group (n=45) patients received atorvastatin 20 mg / d for 3 months. Serum levels of TC、LDL-C and uric acid were measured before and after treatment. According to the initial level of serum uric acid, both groups were divided into hyperuricemia group and normal uric acid group. [Results] (1) Serum levels of TC and LDL-C were significantly decreased after treatment in both rosuvastatin and atorvastatin groups (P<0.05), and there were no significant differences between groups in terms of the percent changes from baseline in TC and LDL-C (P>0.05). (2) Serum levels of uric acid were significantly decreased after treatment in rosuvastatin group amd atorvastatin group. The serum levels of uric acid of patients with hyperuricemia were more significantly reduced than those of patients with normal levels of uric acid (P<0.05). (3) There were no significant differences between rosuvastatin group and atorvastatin group in terms of the percent changes from baseline in serum uric acid in patients with either hyperuricemia or normal levels of uric acid (P>0.05). [Conclusion] The results suggest that rosuvastatin significantly reduce serum uric acid levels as well as cholesterol levels in patients with hypercholesterolemia, especially in patients with hyperuricemia, and there is no difference between rosuvastatin and atorvastatin in lowering serum uric acid levels.